95 related articles for article (PubMed ID: 35078992)
1. Correction: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
Cell Death Dis; 2022 Jan; 13(1):82. PubMed ID: 35078992
[No Abstract] [Full Text] [Related]
2. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
[TBL] [Abstract][Full Text] [Related]
3. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA; Ebert EBF; Clement MS; Winther-Larsen A; Meldgaard P; Sorensen B
Lung Cancer; 2019 Sep; 135():92-96. PubMed ID: 31447008
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
[TBL] [Abstract][Full Text] [Related]
5. hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3.
Dobson JR; Taipaleenmäki H; Hu YJ; Hong D; van Wijnen AJ; Stein JL; Stein GS; Lian JB; Pratap J
Cancer Cell Int; 2014; 14():73. PubMed ID: 25120384
[TBL] [Abstract][Full Text] [Related]
6. RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.
Zhao L; Li N; Yu JK; Tang HT; Li YL; He M; Yu ZJ; Bai XF; Zheng ZH; Wang EH; Wei MJ
Braz J Med Biol Res; 2014 Jan; 47(1):24-34. PubMed ID: 24345874
[TBL] [Abstract][Full Text] [Related]
7. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.
Fang Y; Shen H; Cao Y; Li H; Qin R; Chen Q; Long L; Zhu XL; Xie CJ; Xu WL
Braz J Med Biol Res; 2014 Jan; 47(1):60-9. PubMed ID: 24519092
[TBL] [Abstract][Full Text] [Related]
8. miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy.
Raut SK; Singh GB; Rastogi B; Saikia UN; Mittal A; Dogra N; Singh S; Prasad R; Khullar M
Mol Cell Biochem; 2016 Jun; 417(1-2):191-203. PubMed ID: 27221738
[TBL] [Abstract][Full Text] [Related]
9. Silencing of fanconi anemia complementation group f exhibits potent chemosensitization of mitomycin C activity in breast cancer cells.
Yu J; Zhao L; Li Y; Li N; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
J Breast Cancer; 2013 Sep; 16(3):291-9. PubMed ID: 24155758
[TBL] [Abstract][Full Text] [Related]
10. MiR-30c-5p mediates the effects of panax notoginseng saponins in myocardial ischemia reperfusion injury by inhibiting oxidative stress-induced cell damage.
Wang L; Chen X; Wang Y; Zhao L; Zhao X; Wang Y
Biomed Pharmacother; 2020 May; 125():109963. PubMed ID: 32036220
[TBL] [Abstract][Full Text] [Related]
11. MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer.
Wu YL; Hsu NY; Cheau-Feng Lin F; Lee H; Cheng YW
Surgery; 2016 Dec; 160(6):1591-1598. PubMed ID: 27506865
[TBL] [Abstract][Full Text] [Related]
12. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.
Yang H; Ren L; Wang Y; Bi X; Li X; Wen M; Zhang Q; Yang Y; Jia Y; Li Y; Zang A; Wei Y; Dai G
Cell Death Dis; 2020 Oct; 11(10):851. PubMed ID: 33051436
[TBL] [Abstract][Full Text] [Related]
13. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2.
Zeng H; Wang L; Wang J; Chen T; Li H; Zhang K; Chen J; Zhen S; Tuluhong D; Li J; Wang S
Arch Biochem Biophys; 2018 Aug; 651():52-60. PubMed ID: 29802821
[TBL] [Abstract][Full Text] [Related]
14. SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.
Chen X; Wang YW; Gao P
J Exp Clin Cancer Res; 2018 May; 37(1):100. PubMed ID: 29743122
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
16. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer.
Lai YH; Chen J; Wang XP; Wu YQ; Peng HT; Lin XH; Wang WJ
J Exp Clin Cancer Res; 2017 Jul; 36(1):92. PubMed ID: 28697793
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
18. miR-30c negatively regulates the migration and invasion by targeting the immediate early response protein 2 in SMMC-7721 and HepG2 cells.
Wu W; Zhang X; Liao Y; Zhang W; Cheng H; Deng Z; Shen J; Yuan Q; Zhang Y; Shen W
Am J Cancer Res; 2015; 5(4):1435-46. PubMed ID: 26101708
[TBL] [Abstract][Full Text] [Related]
19. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.
Tanic M; Yanowsky K; Rodriguez-Antona C; Andrés R; Márquez-Rodas I; Osorio A; Benitez J; Martinez-Delgado B
PLoS One; 2012; 7(6):e38847. PubMed ID: 22701724
[TBL] [Abstract][Full Text] [Related]
20. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.
Wang Y; Huang JW; Calses P; Kemp CJ; Taniguchi T
Cancer Res; 2012 Aug; 72(16):4037-46. PubMed ID: 22761336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
